Related Experiment Video
Updated: Jan 17, 2026
05:38
The Effect of Anti-Fatigue Decoction on the Behaviors and Serological Indicators in a Central Fatigue Rat Model
Published on: April 12, 2024
568
PHARMACOLOGICAL TREATMENTS FOR FATIGUE IN INFLAMMATORY BOWEL DISEASE PATIENTS: AN INTEGRATIVE REVIEW.
Tayane Morais1, Genalva Couto1, Raquel Rocha2
1Universidade do Estado da Bahia, Pós-graduação stricto sensu em Ciências Farmacêuticas, Salvador, Bahia, Brasil.
Arquivos De Gastroenterologia
|January 15, 2026
Summary
Fatigue in Inflammatory Bowel Disease (IBD) is common. While some drugs like vedolizumab and upadacitinib show promise, more research is needed for effective pharmacological treatments.
Area of Science:
- Gastroenterology
- Pharmacology
- Clinical Research
Background:
- Fatigue is a significant and debilitating symptom for patients with Inflammatory Bowel Disease (IBD).
- It negatively impacts patients' quality of life, work, and emotional well-being.
- Current pharmacological treatments for IBD-related fatigue are not well-established, highlighting a need for research.
Purpose of the Study:
- To conduct an integrative review of existing pharmacological treatments for fatigue in patients diagnosed with Inflammatory Bowel Disease (IBD).
Main Methods:
- Searched PubMed, Lilacs, SciElo, and Cochrane databases for studies published between January 1, 2017, and December 31, 2024.
- Included studies focused on fatigue assessment and pharmacological interventions for IBD patients.
- Used keywords: (inflammatory bowel disease) AND (fatigue) AND (drug therapy).
Main Results:
- Ten studies involving 2,935 patients (Crohn's disease, ulcerative colitis) met the criteria.
- Vitamin B12 was ineffective; high-dose thiamine showed mixed results.
- Vedolizumab, upadacitinib, and modafinil demonstrated potential in reducing fatigue symptoms.
Conclusions:
- Pharmacological treatments for IBD fatigue are limited, with insufficient data.
- Effective therapies could improve patient well-being, social interaction, and employability.
- Further randomized clinical trials are essential to advance understanding and develop effective treatments.
More Related Videos
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
521
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
521
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
643
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
643
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
437
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
437
01:29Drugs for Treatment of Ulcerative Colitis in IBD
460
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
460
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
492
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
492